CTI BioPharma Announces FDA Accelerated Approval of VONJO™ (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia

Press/Media

Period28 Feb 2022 → 1 Mar 2022

Media coverage

79

Media coverage